• A roadmap to ALS prevention: strategies and priorities

  • 2023/06/15
  • 再生時間： 38 分
  • ポッドキャスト

A roadmap to ALS prevention: strategies and priorities

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Michael Benatar (2) about his recently published article, "A roadmap to ALS prevention: strategies and priorities". This explores a new approach to Amyotrophic lateral sclerosis, with an emphasis on earlier treatment before significant damage has occurred. This is important due to the limited capacity of the central nervous system to repair itself. The researchers involved sought to understand contributing factors for ALS risk, and to identify high-risk groups for further study.

    Note: The genetic therapy referred to as Tofersen, under review at the time of recording, has been approved by the FDA: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene

    You can read the paper at the following link: https://jnnp.bmj.com/content/94/5/399

    (1) Warren Alpert Medical School, Brown University, Rhode Island, USA

    (2) Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA

    Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated.

    Follow JNNP on twitter: @JNNP_BMJ
    続きを読む 一部表示

あらすじ・解説

In this episode, JNNP's new podcast host Dr. Saima Chaudhry (1) speaks with Dr. Michael Benatar (2) about his recently published article, "A roadmap to ALS prevention: strategies and priorities". This explores a new approach to Amyotrophic lateral sclerosis, with an emphasis on earlier treatment before significant damage has occurred. This is important due to the limited capacity of the central nervous system to repair itself. The researchers involved sought to understand contributing factors for ALS risk, and to identify high-risk groups for further study.

Note: The genetic therapy referred to as Tofersen, under review at the time of recording, has been approved by the FDA: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene

You can read the paper at the following link: https://jnnp.bmj.com/content/94/5/399

(1) Warren Alpert Medical School, Brown University, Rhode Island, USA

(2) Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA

Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated.

Follow JNNP on twitter: @JNNP_BMJ
続きを読む 一部表示

A roadmap to ALS prevention: strategies and prioritiesに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。